MX2013011090A - Ensayo de psa y reactivo para el mismo. - Google Patents

Ensayo de psa y reactivo para el mismo.

Info

Publication number
MX2013011090A
MX2013011090A MX2013011090A MX2013011090A MX2013011090A MX 2013011090 A MX2013011090 A MX 2013011090A MX 2013011090 A MX2013011090 A MX 2013011090A MX 2013011090 A MX2013011090 A MX 2013011090A MX 2013011090 A MX2013011090 A MX 2013011090A
Authority
MX
Mexico
Prior art keywords
psa
carriers
assay method
reagent therefor
âμm
Prior art date
Application number
MX2013011090A
Other languages
English (en)
Other versions
MX347002B (es
Inventor
Shinya Nakayama
Yuki Takahashi
Tomo Shimizu
Yasushi Nakamura
Shinichiro Kitahara
Original Assignee
Sekisui Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sekisui Medical Co Ltd filed Critical Sekisui Medical Co Ltd
Publication of MX2013011090A publication Critical patent/MX2013011090A/es
Publication of MX347002B publication Critical patent/MX347002B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporciona un método para el ensayo simple y altamente exacto de PSA por una reacción de una etapa que no utiliza portadores que tienen diferentes tamaños de grano promedio. También se proporciona un reactivo para el mismo. El método de ensayo de PSA comprende sensibilizar portadores insolubles que tienen el mismo tamaño de grano promedio dentro de un rango mayor a 0.20 µm pero 0.40 µm o menos utilizando dos tipos de anticuerpos monoclonales anti-PSA que tienen diferentes epítopos que son anticuerpos monoclonales anti-PSA que reaccionarán con tanto PSA libre como PSA-ACT, que es un compuesto de PSA libre y al-antiquimotripsina, y poner en contacto los portadores con una muestra en la presencia de un promotor de agregación.
MX2013011090A 2011-03-28 2012-03-28 Ensayo de psa y reactivo para el mismo. MX347002B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011069161 2011-03-28
PCT/JP2012/058056 WO2012133482A1 (ja) 2011-03-28 2012-03-28 Psaの測定方法及びその試薬

Publications (2)

Publication Number Publication Date
MX2013011090A true MX2013011090A (es) 2013-12-16
MX347002B MX347002B (es) 2017-04-07

Family

ID=46931192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011090A MX347002B (es) 2011-03-28 2012-03-28 Ensayo de psa y reactivo para el mismo.

Country Status (11)

Country Link
US (2) US20140080143A1 (es)
EP (1) EP2698633B1 (es)
JP (1) JP6110786B2 (es)
KR (1) KR101835918B1 (es)
CN (2) CN103443628A (es)
AU (1) AU2012233635B2 (es)
BR (1) BR112013024686B8 (es)
CA (1) CA2831398C (es)
MX (1) MX347002B (es)
MY (1) MY165647A (es)
WO (1) WO2012133482A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9939433B2 (en) * 2011-12-28 2018-04-10 Sekisui Medical Co., Ltd. Latex particles for measuring particle agglutination
US10067127B2 (en) * 2012-09-28 2018-09-04 Sekisui Medical Co., Ltd. Immunological detection method and immunological detection reagent
CN105640991A (zh) * 2016-01-06 2016-06-08 奥思达干细胞有限公司 一种治疗前列腺癌的car-t细胞制剂及其制备方法
CN110392831B (zh) * 2017-01-27 2023-09-05 豪夫迈·罗氏有限公司 用于在相互作用测定中调节信号强度的方法
MX2020002850A (es) * 2017-09-19 2020-07-24 Regeneron Pharma Metodos para reducir la formacion de particulas y composiciones formadas a partir de estas.
CN108802392A (zh) * 2018-08-29 2018-11-13 上海市东方医院 一种用于诊断前列腺癌的层析试纸条及其制备方法和应用
JP7421711B2 (ja) * 2018-10-09 2024-01-25 積水メディカル株式会社 ロイシンリッチα２グリコプロテインの免疫測定方法及び測定試薬
CN117192134A (zh) * 2023-09-14 2023-12-08 宁波美康盛德生物科技有限公司 一种氧化型低密度脂蛋白的检测试剂盒、检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5185264A (en) * 1990-11-09 1993-02-09 Abbott Laboratories Diluent buffer and method for diluting an assay component
EP0789032A2 (en) * 1996-02-01 1997-08-13 Bayer Corporation Method for preparing a monoclonal antibody that provides an equimolar response to free and complexed analyte in a monoclonal/polyclonal sandwich immunoassay
JP3652029B2 (ja) * 1996-10-16 2005-05-25 積水化学工業株式会社 高感度免疫測定法
JP2001108681A (ja) 1999-10-07 2001-04-20 Sysmex Corp 免疫凝集測定用試薬及び測定方法
JP4577747B2 (ja) * 2001-06-05 2010-11-10 和光純薬工業株式会社 免疫学的測定法用凝集促進剤
CN100396331C (zh) 2001-07-02 2008-06-25 积水化学工业株式会社 用于分析试剂的载体颗粒胶乳和分析试剂
JP4241301B2 (ja) * 2003-09-30 2009-03-18 和光純薬工業株式会社 免疫学的測定用試薬
EP1830189B1 (en) * 2004-12-24 2012-09-05 Sekisui Medical Co., Ltd. Reagent and method for assaying prostate specific antigen
CN102565397B (zh) * 2005-12-07 2015-07-08 积水医疗株式会社 防止血清干扰及提高抗磷脂抗体测定剂保存稳定性的方法
JP2007163319A (ja) * 2005-12-14 2007-06-28 Sanyo Chem Ind Ltd 免疫測定法及び免疫測定用試薬キット
WO2007074860A1 (ja) 2005-12-28 2007-07-05 Sekisui Medical Co., Ltd. 凝集測定用試薬及び凝集測定方法
KR101433974B1 (ko) * 2006-07-24 2014-08-25 세키스이 메디칼 가부시키가이샤 응집 저해 측정법 및 응집 저해 측정용 시약
JP5398697B2 (ja) * 2008-02-29 2014-01-29 積水メディカル株式会社 高分子量アディポネクチンの測定方法
EP2295969B1 (en) * 2008-07-04 2016-05-18 Sekisui Medical Co., Ltd. Method for enhancing sensitivity or method for avoiding influence of hemoglobin in immunological measurement
JP5554247B2 (ja) 2008-12-04 2014-07-23 積水メディカル株式会社 ヒト体液中のシスタチンｃ測定方法
US9939433B2 (en) * 2011-12-28 2018-04-10 Sekisui Medical Co., Ltd. Latex particles for measuring particle agglutination
JP5430804B1 (ja) * 2012-03-30 2014-03-05 積水メディカル株式会社 粒子凝集測定用ラテックス粒子
EP2902785B1 (en) * 2012-09-27 2017-07-26 Sekisui Medical Co., Ltd. Latex particles for particle aggregation measurement

Also Published As

Publication number Publication date
KR101835918B1 (ko) 2018-03-07
CN103443628A (zh) 2013-12-11
AU2012233635B2 (en) 2016-09-08
BR112013024686A2 (pt) 2016-12-20
AU2012233635A1 (en) 2013-10-17
CN105424936A (zh) 2016-03-23
CN105424936B (zh) 2018-09-21
EP2698633A1 (en) 2014-02-19
MY165647A (en) 2018-04-18
MX347002B (es) 2017-04-07
CA2831398A1 (en) 2012-10-04
EP2698633A4 (en) 2014-12-17
US20160011181A1 (en) 2016-01-14
EP2698633B1 (en) 2017-10-11
US10119963B2 (en) 2018-11-06
WO2012133482A1 (ja) 2012-10-04
CA2831398C (en) 2020-06-09
BR112013024686B8 (pt) 2022-05-03
BR112013024686B1 (pt) 2020-12-29
JP6110786B2 (ja) 2017-04-05
US20140080143A1 (en) 2014-03-20
KR20140015488A (ko) 2014-02-06
JPWO2012133482A1 (ja) 2014-07-28

Similar Documents

Publication Publication Date Title
MX2013011090A (es) Ensayo de psa y reactivo para el mismo.
NZ628314A (en) Cd47 antibodies and methods of use thereof
MX2013004172A (es) Metodos y kits para la deteccion de células tumorales circulantes en pacientes pancreáticos por medio del uso de captura poliespecífica y reactivos de detección de cocteles.
MX362075B (es) Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
EA201590671A1 (ru) Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли
MX2014001377A (es) Metodo para detectar cancer pancreatico.
MX2016001573A (es) Ensayos para timp2 con mejor rendimiento en muestras biológicas.
CR20110559A (es) Anticuerpos específicos para cadherina-17
MX2016005834A (es) Ensayos para igfbp7 con mejor rendimiento en muestras biológicas.
WO2010096674A3 (en) A+ biomarker assays
WO2010111299A3 (en) Synthetic antibodies
SG10201906124XA (en) Foetal nucleated red blood cell detection
RU2012148244A (ru) Способ диагностики онкологических заболеваний и иммуноферментный набор для его осуществления
WO2011074802A3 (ko) 전립선암 진단용 키트 및 진단방법
RU2015104737A (ru) Способ обнаружения мультиспецифического связывающего агента
WO2009003082A3 (en) Immunological compositions as cancer biomarkers and/or therapeutics
MX2015004419A (es) Deteccion de analito y determinacion de concentracion de analito mediante uso de perlas magnetizables.
SG11201809558PA (en) Anti-human hemoglobin monoclonal antibody or antibody kit, insoluble carrier particle to which anti-human hemoglobin monoclonal antibody is immobilized, and measurement reagent and measurement method using same
WO2012061904A8 (en) Histone protein ubiquitination as a cancer biomarker
WO2012174569A3 (en) New markers for early diagnosis of ovarian cancer, monitoring during therapy, and new therapy options during and after chematherapy
WO2012135635A3 (en) Ovarian cancer biomarkers
GB201021623D0 (en) Detection of acute myeloid leukaemia
Chen et al. Anti-cytokeratin CAM 5.2 does not act as a surrogate of the cytokeratin 8/18 monoclonal antibody. Comment on:" Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma", in J Cutan Pathol 2009; 36: 543
GB201107557D0 (en) Method
WO2007090294A8 (en) Anti-bfa4 monoclonal antibodies and for cancer diagnostics and treatment

Legal Events

Date Code Title Description
FG Grant or registration